What this pack is
DESYREL / trazodone is the brand name in this record; trazodone hydrochloride is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
DESYREL / trazodoneGeneric nametrazodone hydrochloride
How this medicine works
The label relates trazodone's antidepressant activity to serotonin reuptake and receptor effects, but the therapeutic mechanism cannot determine individual suitability, sleep use, superiority, tablet count or combination with other neuropsychiatric medicines.
Read source: United States ↗Current regulatory record · reviewed 2026-08-30More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- DESYREL / trazodone
- Generic name
- trazodone hydrochloride
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
4 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. generic DailyMed label (updated 23 Jan 2026)
50 mg trazodone hydrochloride per tablet; 100-tablet bottle
- Product code
- NDC 70771-1128-1
- Form and route
- trazodone hydrochloride oral tablet · oral (exact-product identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- trazodone hydrochloride
- 50 mglabelled amount per tablet; not an individual's tablet count, sleep use, splitting, dose change, stopping or switching instruction
- Package
- 100 tablets per bottle
United States label · Current U.S. generic DailyMed label (updated 23 Jan 2026)
100 mg trazodone hydrochloride per tablet; 100-tablet bottle
- Product code
- NDC 70771-1129-1
- Form and route
- trazodone hydrochloride oral tablet · oral (exact-product identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- trazodone hydrochloride
- 100 mglabelled amount per tablet; not an individual's tablet count, sleep use, splitting, dose change, stopping or switching instruction
- Package
- 100 tablets per bottle
United States label · Current U.S. generic DailyMed label (updated 23 Jan 2026)
150 mg trazodone hydrochloride per tablet; 100-tablet bottle
- Product code
- NDC 70771-1130-1
- Form and route
- trazodone hydrochloride oral tablet · oral (exact-product identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- trazodone hydrochloride
- 150 mglabelled amount per tablet; not an individual's tablet count, sleep use, splitting, dose change, stopping or switching instruction
- Package
- 100 tablets per bottle
United States label · Current U.S. generic DailyMed label (updated 23 Jan 2026)
300 mg trazodone hydrochloride per tablet; 100-tablet bottle
- Product code
- NDC 70771-1131-1
- Form and route
- trazodone hydrochloride oral tablet · oral (exact-product identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- trazodone hydrochloride
- 300 mglabelled amount per tablet; not an individual's tablet count, sleep use, splitting, dose change, stopping or switching instruction
- Package
- 100 tablets per bottle
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
DESYREL / trazodone label reading: separate brand history, current generics and sleep-use assumptions
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The current generic label identifies trazodone hydrochloride for major depressive disorder in adults. Common discussion of sleep use does not let this site derive an individual's sleep use, tablet count, timing, dose change or stopping plan. Check the exact product, mg per tablet, actual prescription, full medicine list and target-market label.
- 50, 100, 150 and 300 mg are labelled amounts per tablet for four current generic products. They are not a calculator for adding numbers, assembling a strength or choosing tablets from sleep duration. A score must be checked against the exact manufacturer label and prescription rather than treated as automatic permission to split.
- Do not drive or operate hazardous machinery when somnolence, dizziness or impaired cognitive/motor performance occurs. Older adults and people using blood-pressure medicines, diuretics, sedatives, alcohol or other CNS depressants need priority review for orthostatic hypotension, syncope, falls, dehydration and the complete medicine list.
- Older adults, people using diuretics or those who are volume depleted also need review for hyponatraemia. Marked weakness, headache, confusion, unsteady gait, falls, seizures or altered awareness needs timely medical assessment rather than attribution to age or poor sleep alone.
- Another serotonergic antidepressant, tramadol, lithium, buspirone, amphetamine, tryptophan, St John's wort, an MAOI, linezolid or intravenous methylene blue on the list requires priority review for serotonin syndrome and contraindication boundaries. Do not self-combine, time-separate or alternate them.
- QT prolongation or another rhythm condition, low potassium/magnesium, related medicines, or aspirin, NSAIDs, antiplatelets or anticoagulants on the list requires priority review of rhythm and bleeding risk. Fainting, chest pain, marked palpitations, severe bleeding or another acute serious concern requires immediate local emergency care.
- Thoughts of self-harm/suicide, marked behavioural change, a severe allergy-like reaction, a persistent painful erection or another acute serious concern requires immediate local emergency or crisis support. Do not wait for a webpage or try to counteract it with another pack.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-30
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. generic trazodone hydrochloride tablet label, Medication Guide and exact package panels (updated 23 Jan 2026) ↗Current regulatory record · reviewed 2026-08-30
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-08-30FDA: DESYREL (trazodone hydrochloride) NDA 018207 brand-label archive (2018) ↗reviewed 2026-08-30
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about DESYREL / trazodone (trazodone hydrochloride). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
DESYREL / trazodone is the brand in this record and trazodone hydrochloride is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. generic trazodone hydrochloride tablet label, Medication Guide and exact package panels (updated 23 Jan 2026) ↗Current regulatory record · reviewed 2026-08-30
- FDA: DESYREL (trazodone hydrochloride) NDA 018207 brand-label archive (2018) ↗reviewed 2026-08-30
HOW IT WORKS · NOT A TREATMENT PLAN
How trazodone works: serotonergic activity cannot determine an individual's sleep or antidepressant plan
- ‘May cause drowsiness’ does not mean ‘is automatically a sleeping pill’ and does not justify self-starting or combining with DAYVIGO, BELSOMRA, AMBIEN, benzodiazepines, antihistamines or alcohol.
- Shared serotonergic activity does not permit milligram conversion, rotation or combination of trazodone with CELEXA, LEXAPRO, ZOLOFT, PROZAC, PAXIL, CYMBALTA, EFFEXOR, TRINTELLIX or another product.
- Brand history, current generics and a shared active ingredient can establish regulatory and pack-checking routes, but mechanism, trade name or a pack image cannot determine which product suits an individual, whether it is substitutable or whether it should be stopped or switched.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. generic trazodone hydrochloride tablet label, Medication Guide and exact package panels (updated 23 Jan 2026) ↗Current regulatory record · reviewed 2026-08-30
- FDA: DESYREL (trazodone hydrochloride) NDA 018207 brand-label archive (2018) ↗reviewed 2026-08-30
- FDA Drugs@FDA: DESYREL / trazodone hydrochloride NDA 018207 application record ↗Current regulatory record · reviewed 2026-08-30
SOURCE-TRACEABLE ARCHIVE
DESYREL / trazodonetrazodone hydrochloride
This page includes an exact current U.S. public-label package panel for DESYREL / trazodone, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. DESYREL approval
FDA labelling lists 1981 as the initial U.S. approval year for DESYREL. This historical point does not establish a current brand pack, holder, supply or purchase availability.
FDA: DESYREL (trazodone hydrochloride) NDA 018207 brand-label archive (2018) ↗DESYREL brand-label archive
FDA publishes a 2018 NDA 018207 brand label preserving indication, boxed-warning and safety-reading paths. The page explicitly treats it as historical brand material.
FDA: DESYREL (trazodone hydrochloride) NDA 018207 brand-label archive (2018) ↗Current generic label updated
The current DailyMed label displays 50, 100, 150 and 300 mg 100-tablet bottle panels. A label does not establish local stock, purchase availability or individual suitability.
DailyMed (NLM): current U.S. generic trazodone hydrochloride tablet label, Medication Guide and exact package panels (updated 23 Jan 2026) ↗
MARKET SCOPE
Market-record boundary
United States
Historical DESYREL brand label, NDA record and current exact generic packs linkedBrand history and current generic products remain separate; generic packs are not passed off as DESYREL and a historical label is not described as live supply.
Mainland China, Japan, EU and other markets
Current regulatory product records not yet establishedNo approval, pack, supply, originator/generic relationship or interchangeability in another market is inferred from U.S. brand history, generic name or milligram figures.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Is trazodone a sleeping pill?
The cited U.S. label indicates major depressive disorder in adults. Somnolence is a safety and fall-prevention cue, not webpage confirmation of a sleep use, time or tablet count for anyone. The treating team must explain the actual prescription purpose and directions.
Does a score mean I can split it myself?
Do not rely on a score alone. Manufacturer, strength, tablet design and label can differ; check the exact NDC, manufacturer label and prescription. The site does not turn pack or tablet appearance into an individual splitting plan.
Why does a DESYREL pack differ from the generic packs shown here?
DESYREL is a historical brand identity. The four current pack images come from a separate U.S. generic label. A shared ingredient does not mean the same manufacturer, pack or current brand supply.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.